We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+17.01%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.66B
AUM Growth
+$1B
Cap. Flow
+$784M
Cap. Flow %
13.85%
Top 10 Hldgs %
43.17%
Holding
164
New
34
Increased
29
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$47.7M
2
ARGX icon
argenx
ARGX
+$47.4M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$44.5M
4
IMA
ImageneBio Inc
IMA
+$44.2M
5
ACHL
Achilles Therapeutics
ACHL
+$37.3M

Top Sells

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$89.7M
2
Z icon
Zillow
Z
+$66.8M
3
ONC
BeOne Medicines Ltd
ONC
+$49.7M
4
BABA icon
Alibaba
BABA
+$46.5M
5
QURE icon
uniQure
QURE
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 68.71%
2 Consumer Discretionary 8.71%
3 Technology 1.72%
4 Communication Services 0.79%
5 Real Estate 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$464M 8.19%
14,818,300
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.03B
$418M 7.38%
71,178,364
– –
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
$296M 5.23%
850,000
-150,000
-15% -$49.7M
SEER icon
4
Seer Inc
SEER
$114M
$280M 4.94%
5,588,366
-252,545
-4% -$14.8M
C icon
5
CALL
Citigroup
C
$213B
$218M 3.86%
+3,000,000
New +$200M
GM icon
6
CALL
General Motors
GM
$80.9B
$201M 3.55%
+3,500,000
New +$186M
XLRN
7
DELISTED
Acceleron Pharma
XLRN
$190M 3.35%
1,400,000
– –
RUBY
8
DELISTED
Rubius Therapeutics, Inc
RUBY
$129M 2.29%
4,883,791
+1,104,878
+29% +$16.1M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$124M 2.19%
725,000
+225,000
+45% +$44.5M
ARGX icon
10
argenx
ARGX
$55.2B
$124M 2.19%
450,000
+150,000
+50% +$47.4M
MORF
11
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$115M 2.03%
1,819,186
+167,500
+10% +$7.69M
FATE icon
12
Fate Therapeutics
FATE
$275M
$107M 1.89%
1,300,000
-100,000
-7% -$9.58M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.3B
$106M 1.87%
750,000
-50,000
-6% -$7.52M
SRRK icon
14
Scholar Rock
SRRK
$5.88B
$101M 1.79%
2,000,000
-100,000
-5% -$5.53M
BNTX icon
15
BioNTech
BNTX
$23.5B
$98.3M 1.74%
900,000
-100,000
-10% -$10.6M
IGMS
16
DELISTED
IGM Biosciences
IGMS
$86.3M 1.52%
1,125,000
-75,000
-6% -$6.83M
F icon
17
CALL
Ford
F
$60.9B
$85.8M 1.52%
+7,000,000
New +$80.1M
INTC icon
18
CALL
Intel
INTC
$413B
$83.2M 1.47%
+1,300,000
New +$77.5M
GBIO
19
DELISTED
Generation Bio
GBIO
$80.1M 1.42%
281,419
– –
BAC icon
20
CALL
Bank of America
BAC
$429B
$77.4M 1.37%
+2,000,000
New +$69M
TGTX icon
21
TG Therapeutics
TGTX
$8.19B
$72.3M 1.28%
1,500,000
– –
XBI icon
22
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
$67.8M 1.2%
+500,000
New +$74.9M
BMY icon
23
CALL
Bristol-Myers Squibb
BMY
$129B
$63.1M 1.12%
1,000,000
– –
SDGR icon
24
Schrodinger
SDGR
$1.13B
$60.8M 1.07%
797,445
– –
KLRS
25
Kalaris Therapeutics
KLRS
$80.9M
$54.4M 0.96%
101,016
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2021 Portfolio in Review

As of Q1 2021, Artal Group held 164 positions worth $5.66B, up 21% from $4.66B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group deployed $784M of net new capital in Q1 2021, opening 34 new positions and adding to 29 existing holdings. Its largest new stake was Intel: 800,000 shares worth $51.2M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 77% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was GDS Holdings, an estimated $89.7M trimmed.

  • Artal Group's largest Q1 2021 buy was Intel: 800,000 shares worth $51.2M.
  • Artal Group added most to argenx in Q1 2021, an estimated $47.4M increase.
  • Artal Group's biggest Q1 2021 reduction was GDS Holdings, cutting an estimated $89.7M.
  • Artal Group fully exited Alibaba in Q1 2021, selling an estimated $46.5M.
  • Artal Group's ten largest holdings make up 43% of its $5.66B portfolio in Q1 2021.
  • Artal Group opened 34 new positions and closed 18 in Q1 2021.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $5.66B.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.